Lundbeck boosts sales in schizophrenia and migraine drugs

Danish pharmaceutical company Lundbeck has accelerated the sales of its key products in the third quarter, reporting a revenue of 5.7 billion DKK—a 16% increase from the same quarter in 2023. The surge is attributed to the strategic brands, including Rexulti for schizophrenia treatment, which saw a 21% increase in sales. Migraine prevention drug Vyepti also showed significant growth, earning 774 million DKK, a 74% rise compared to the same period last year, now holding a 9.4% share of the US prevention market. Lundbeck’s earnings in the third quarter rose to 777 million DKK, up 15% year-over-year. The company announced in October its pending acquisition of Longboard Pharmaceuticals for around 17 billion DKK, awaiting regulatory approvals. Lundbeck CEO Charl van Zyl stated that finalizing the Longboard acquisition is a top priority to secure the epilepsy treatment Bexicaserin.